SMM with transfusion, accounting for comorbidities, demographics and hospital factors, with risk ratios (RR) and 95% confidence intervals (CI) as measures of effect. Population weights were applied to create national estimates. RESULTS: 1,081,343 deliveries to women with twins from 1998 to 2014 were included in this analysis. Risk for SMM both with and without transfusion was lowest for women 25 to 34 (Figure 1 ). Risk for SMM with transfusion was bimodal, with the highest risk among women 15-17 and 40-54. For SMM without transfusion, the risk was highest for women 40-54. In the adjusted model for SMM with transfusion, women 45-54 were at 188% higher risk (95% CI 134-255%) and women 40-44 were at 109% higher risk (95% CI 83-140%) than those age 25-29; risks for women 15-17 and 18-24 were not significantly different. In evaluating risk for DIC and hysterectomy, the likelihood of both outcomes increased significantly with age (p<0.01). Compared to women 25-29, women aged 45-54 were at 7.7 times greater risk (95% CI 4.7-12.4) for hysterectomy while women 40-44 were at 5.7 times greater risk (95% CI 4.1-7.9) (Figure 2 ). Women 40-44 were at 84% higher risk of DIC (95% CI 45-135%). CONCLUSION: Overall risk for severe morbidity in twin pregnancies was highest for women 40 and older, as was risk for specific causes of morbidity such as hysterectomy and DIC. While other research has found that twin neonatal outcomes are generally similar for older and younger women, maternal outcome differentials are larger. Overall risk for severe morbidity (SMM), based on the Centers for Disease Control and Prevention criteria, was analyzed stratifying by maternal age, along with risk for specific outcomes such acute heart failure or pulmonary edema (AHF/PE), eclampsia, and acute renal failure (ARF). SMM was assessed with and without transfusion. Loglinear models were created to assess the risk for SMM with transfusion, accounting for comorbidities, demographics and hospital factors, with risk ratios (RR) and 95% confidence intervals (CI) as measures of effect. Population weights were applied to create national estimates. RESULTS: 2,522,093 deliveries to women with preeclampsia from 1998 to 2014 were included in this analysis. Risk for SMM both with and without transfusion was lowest for women 25 to 34 (Figure 1 ). Risk for SMM was bimodal, with the highest risk among women 15-17 and 45-54. In the adjusted model, women 15-17 were at 30% higher risk (95%CI 22-38%) and women 45-54 were at 104% higher risk (95% CI 70-144%) for SMM with transfusion. In evaluating specific morbidity outcomes (Figure 2 ), risk for ARF and AHF/PE increased statistically by maternal age group (p<0.01). Compared to women 25-29, women aged 45-54 were at 228% higher risk for AHF/PE (95% CI 118-393%) and 276% higher risk for ARF (95% CI 157-451%). In comparison, eclampsia was most common among young women, decreasing significantly across age groups (p<0.01). Women aged 15-17 were at 183% higher risk for eclampsia than women 25-29 (95% 161-206%) while women 18-24 were at 58% higher risk (95% CI 50-67%). CONCLUSION: Overall risk for severe morbidity in the setting of preeclampsia is highest at the extremes of maternal age. However, specific pregnancy complications are not distributed evenly across ages, with eclampsia most common among younger women and acute renal and heart failure more common among older women.
Maternal age and preeclampsia outcomes
Jean-Ju Sheen, Yongmei Huang, Jason D. Wright, Dena Goffman, Mary E. D'Alton, Alexander M. Friedman Columbia University Irving Medical Center, New York, NY OBJECTIVE: The objective of this study was to characterize the risk for severe maternal morbidity and other pregnancy complications by maternal age during delivery hospitalizations complicated by preeclampsia. STUDY DESIGN: This retrospective cohort study utilized the Nationwide Inpatient Sample (NIS) from the Agency for Healthcare Research and Quality for the years 1998 to 2014. Women aged 15 to 54 with a diagnosis of preeclampsia were included. Age was categorized as 15-17, 18-24, 25-29, 30-34, 35-39, 40-44, and 45-54 years. Overall risk for severe morbidity (SMM), based on the Centers for Disease Control and Prevention criteria, was analyzed stratifying by maternal age, along with risk for specific outcomes such acute heart failure or pulmonary edema (AHF/PE), eclampsia, and acute renal failure (ARF). SMM was assessed with and without transfusion. Loglinear models were created to assess the risk for SMM with transfusion, accounting for comorbidities, demographics and hospital factors, with risk ratios (RR) and 95% confidence intervals (CI) as measures of effect. Population weights were applied to create national estimates. RESULTS: 2,522,093 deliveries to women with preeclampsia from 1998 to 2014 were included in this analysis. Risk for SMM both with and without transfusion was lowest for women 25 to 34 (Figure 1 ). Risk for SMM was bimodal, with the highest risk among women 15-17 and 45-54. In the adjusted model, women 15-17 were at 30% higher risk (95%CI 22-38%) and women 45-54 were at 104% higher risk (95% CI 70-144%) for SMM with transfusion. In evaluating specific morbidity outcomes (Figure 2 ), risk for ARF and AHF/PE increased statistically by maternal age group (p<0.01). Compared to women 25-29, women aged 45-54 were at 228% higher risk for AHF/PE (95% CI 118-393%) and 276% higher risk for ARF (95% CI 157-451%). In comparison, eclampsia was most common among young women, decreasing significantly across age groups (p<0.01). Women aged 15-17 were at 183% higher risk for eclampsia than women 25-29 (95% 161-206%) while women 18-24 were at 58% higher risk (95% CI 50-67%). CONCLUSION: Overall risk for severe morbidity in the setting of preeclampsia is highest at the extremes of maternal age. However, specific pregnancy complications are not distributed evenly across ages, with eclampsia most common among younger women and acute renal and heart failure more common among older women.
Poster Session II OBJECTIVE: Vaginal pessaries are a treatment for gravid patients with short cervix. Increased discharge has been a consistent finding in multiple prior investigations and it's etiology has not been elucidated. We aimed to explore variation in cytokine expression following placement of a vaginal pessary in patients with short funneled cervix. We hypothesize that the cytokine expression profile is altered as a consequence of pessary use. STUDY DESIGN: This is a prospective cohort study of patients who received Milex Ò Inflatoball pessaries for shortened cervix. Gestational age-matched controls without cervical shortening served as the control group. Following consent, pessary and control patients underwent collection of sterile vaginal lavage for baseline specimen. Both arms were followed longitudinally and underwent vaginal lavage collection a week later and then monthly. Multiplexed ELISA analyzed 38 cytokines with a broad survey panel. Cytokine levels were compared longitudinally within each arm, between baseline experimental subjects and controls and longitudinal cytokine concentration was compared between the two arms. Pair-wise comparisons were performed using Mann-Whitney U test. RESULTS: Most of the 38 cytokines were below the level of detection. Granulocyte-colony stimulating factor (G-CSF) demonstrated significant differences between pre-and post-pessary arm and post-pessary arm (p<.0001) and baseline pessary arm and baseline control arm (p¼.0003). Interleukin-4 (IL-4) likewise was significantly different between baseline specimens in each arm (p¼.003) and pre-and post-pessary arms (<.0001). Interleukin-6 was expressed differently in pre-and post-pessary arms (p<.0001), baseline pessary and baseline control arms (p¼.0101), and longitudinal pessary and control arms (p<.0001). Interleukin-1-a (IL-1-a) was variably expressed between baseline arms (p<.0001). CONCLUSION: Significant variation in cytokine expression of G-CSF, IL-4, IL-6, and IL-1-a was noted in pessary patients compared with controls. Reduced cytokine expression of IL-1 alpha and G-CSF are noted in patients who underwent pessary placement. However, IL-6 is higher in patients with pessary relative to gestational age-matched controls. Alteration in cytokine expression following pessary placement in gravid patients is expected, however, the allergy-like response is surprising. Additionally, the reduced immune response prior to pessary placement is a novel finding.
320 Marijuana use in women with a hypertensive disorder of pregnancy: Is it safe? OBJECTIVE: Data on the association between marijuana use and pregnancy outcomes is limited. In the general population, marijuana use leads to increased blood pressure, highlighting the need to better understand the potential association between marijuana use and hypertension in pregnancy. Therefore, we assessed the relationship between marijuana use and pregnancy outcomes among women with a hypertensive disorder of pregnancy. STUDY DESIGN: Retrospective cohort study among subjects with a hypertensive disorder of pregnancy that delivered 23 weeks gestation at a single institution (October '13 e April '18). Utilizing ICD-9 and ICD-10 discharge codes, followed by individual chart review, subjects were stratified into two groups by marijuana use: current vs. non -users (never, quit prior to or during pregnancy). We assessed final hypertensive diagnosis, severe features of preeclampsia, and neonatal and maternal outcomes. Differences were analyzed by Fisher's exact, t-test, and logistic regression, with a¼0.05.
RESULTS: From 10,833 deliveries, 1,487 (13.7%) were classified with a hypertensive disorder of pregnancy. 77 subjects (5.2%) actively used marijuana during pregnancy, 1,087 (73.1%) were non-users and 323 (21.7%) had unknown marijuana use and were excluded. Subjects using marijuana were more likely to be younger, covered by public insurance and using other substances compared to non-users (Table 1) . There were no differences in final hypertensive diagnosis for current marijuana users vs. non-users (p¼0.43), although marijuana users were more likely to experience a severe diastolic blood pressure ( 110 mmHg) compared to non-users (p¼0.014). Marijuana use was associated with adverse neonatal outcomes, which remained statistically significant when adjusting for important maternal characteristics (aOR: 1.84, p¼0.017), although this association attenuated when adjusting for other current substance use (aOR: 1.74, p¼0.081) ( Table 2) . CONCLUSION: Marijuana use was associated with adverse neonatal outcomes in women with hypertensive disorders of pregnancy.
